Your email has been successfully added to our mailing list.

×
-0.00860009555661728 -0.00860009555661728 -0.00860009555661728 -0.00143334925943619 -0.020437171524128 -0.0354515050167223 -0.0449187768752987 -0.0635451505016723
Stock impact report

Kamada up 4% on development of coronavirus treatment [Seeking Alpha]

Acasti Pharma, Inc. - Class A (ACST) 
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: acastipharma.com/investors
Company Research Source: Seeking Alpha
Healthcare | On the Move Kamada up 4% on development of coronavirus treatment Mar. 11, 2020 10:14 AM ET Kamada Ltd. (KMDA) Douglas W. House Thinly traded micro cap Kamada Ltd. ( +3.8% announced plan The company will produce the IgG antibody product from plasma derived from donors who have recovered from coronavirus infection, including SARS-CoV-2. It cautions that the product will be highly dependent on the availability of hyperimmune plasma and the regulatory pathway. See all stocks on the move » Now read: Acasti Pharma up 8% on new CaPre patents » Show less Read more
Impact Snapshot
Event Time:
ACST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ACST alerts
Opt-in for
ACST alerts

from News Quantified
Opt-in for
ACST alerts

from News Quantified